Radius Health (RDUS)
NASDAQ:RDUS

Radius Health Stock Analysis & Ratings

RDUS Stock Chart & Stats

Day’s Range$5.53 - $6.25
52-Week Range$4.97 - $23.00
Previous Close$5.84
Volume1.52M
Average Volume (3M)877.92K
Market Cap$297.31M
P/E Ratio-4.1
Beta1.03
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-1.54


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

RDUS FAQ

What was Radius Health’s price range in the past 12 months?
Radius Health lowest stock price was $4.97 and its highest was $23.00 in the past 12 months.
    What is Radius Health’s market cap?
    Radius Health’s market cap is $297.31M.
      What is Radius Health’s price target?
      The average price target for Radius Health is $11.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $14.00 ,the lowest forecast is $10.00. The average price target represents 84.00% Increase from the current price of $6.25.
        What do analysts say about Radius Health?
        Radius Health’s analyst rating consensus is a ‘Hold. This is based on the ratings of 4 Wall Streets Analysts.
          When is Radius Health’s upcoming earnings report date?
          Radius Health’s upcoming earnings report date is Aug 04, 2022 which is in 75 days.
            How were Radius Health’s earnings last quarter?
            Radius Health released its earnings results on May 05, 2022. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.176.
              Is Radius Health overvalued?
              According to Wall Street analysts Radius Health’s price is currently Undervalued.
                Does Radius Health pay dividends?
                Radius Health does not currently pay dividends.
                What is Radius Health’s EPS estimate?
                Radius Health’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Radius Health have?
                Radius Health has 47,570,000 shares outstanding.
                  What happened to Radius Health’s price movement after its last earnings report?
                  Radius Health reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -13.866%.
                    Which hedge fund is a major shareholder of Radius Health?
                    Among the largest hedge funds holding Radius Health’s share is Farallon Capital Management, L.L.C.. It holds Radius Health’s shares valued at 19M.

                      ---

                      Radius Health Stock Analysis

                      Smart Score
                      6
                      Neutral
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $11.50
                      ▲(84.00% Upside)
                      Hold
                      The Radius Health stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Radius Health

                      Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Novartis
                      Zosano Pharma
                      Pfizer
                      Oncternal Therapeutics
                      Eli Lilly & Co

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis